SM 020
Alternative Names: SM-020Latest Information Update: 22 May 2024
At a glance
- Originator SeylanMED
- Developer DermBiont
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Basal cell cancer; Seborrhoeic keratosis; Squamous cell cancer
Most Recent Events
- 25 Mar 2024 Phase-II clinical trials in Basal cell cancer in USA (Topical) (NCT06409195)
- 25 Mar 2024 Phase-II clinical trials in Squamous cell cancer in USA (Topical) (NCT06409195)
- 29 Feb 2024 DermBiont completes enrollment in the phase II trial for Seborrheic keratosis in USA (Topical) (NCT06108024)